Medicis (maker of Restylane) has recently announced submission of Reloxin to the FDA for a BLA (Biologics License Application). This is a good thing for consumers, since Reloxin may become the first real competitor to Botox on the market. It is a form of Botulinum Toxin Type A, and can hopefully provide some competition for the massive Botox market. Currently, the makers of Botox (Allergan) have the only product of its kind on the market here in the States, and the prices seem to reflect this fact. I currently pay over $500 per vial of Botox, which is usually enough to treat only 5 different facial areas, or approximately 1.5-2 patients. This is the main reason why Botox treatments are so expensive. Hopefully the eventual arrival (still not sure when) of Reloxin on the market will bring the prices down, allowing more people to get the Botox they "desperately need!"
Photo credit: dermadoctor.com
Thanks for reading.
Michigan-based Plastic Surgeon
Anthony Youn, M.D.
No comments:
Post a Comment